The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy

AIDS

Volumn 18, Issue 17, 2004, Pages 2313-2318

  Dorrucci, Maria ^a   Valdarchi, Catia ^a   Suligoi, Barbara ^a   Zaccarelli, Mauro ^b   Sinicco, Alessandro ^c   Giuliani, Massimo ^d   Vlahov, David ^e,f   Pezzotti, Patrizio ^a   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^e NEW YORK ACADEMY OF MEDICINE   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HAART; HCV; Progression to AIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; VIRUS HEPATITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 10244242497     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411190-00012     Document Type: Article

References (31)

1. Bica I., McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32:492-497.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced Human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
3. Hogg RS, Heat KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
4. Sherman K, Roustrer S, Chung R, Rajicic N. Hepatitis C prevalence in HIV-infected patients: a cross-sectional analysis of the US ACTG. Antiviral Ther 2000; 5(Suppl. 1):64-65.
5. Lauer C, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
6. Soriano V, Kirk O, Antunes F, Chiodo F. The influence of hepatitis C on the prognosis of HIV: the Euro SIDA Study. XIIIth International AIDS Conference, Durban, July 2000 [abstract ThOrB655].
7. Soriano V, Martin JC, Gonzales-Lahoz J. HIV-1 progression in hepatitis C-infected drug users. Lancet 2001; 357:1361-1362.
8. Wright TL, Hollander H, Pu X, Held MJ, Lipson P, Quan S, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994; 20:1152-1155.
9. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993; 17:117-119.
10. Dorrucci M., Pezzotti P., Phillips AN, Cozzi Lepri A., Rezza G. Coinfection of hepatitis C virus with immunodeficiency virus and progression to AIDS. J Infect Dis 1995; 172:1503-1508.
11. Klein MB, Lalonde RC, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33:365-372.
12. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12:381-388.
13. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss Cohort Study. Lancet 2000; 356:1800-1805.
14. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
15. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987; 126:14-24.
16. Rezza G, Dorrucci M, Pezzotti P, et al. The seroconversion study on the natural history of HIV infection. In: Nicolosi A (editor): HIV Epidemiology: Models and Methods. New York: Raven Press; 1994, pp. 279-289.
17. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341:441.
18. Clayton DG, Hills M. Statistical Models In Epidemiology. Oxford: Oxford University Press; 1993.
19. Collett D. Modelling Survival Data in Medical Research. Chapman and Hall, London, 1994.
20. Detels R, Munoz A, McFarlane G. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-1503.
21. Porter K, Babiker A, Bhaskaran K. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
22. De Luca A, Bugarini R, Lepri AC. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 14(162):2125-2132.
23. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression? JAMA 2002; 288:241-243.
24. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
25. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
26. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
27. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
28. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.
29. Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, et al. Sopravvivenza, progressione in AIDS e livello di immunosoppressione in persone HIV-positive prima e dopo l'introduzione della terapia antiretrovirale di combinazione con tre o più farmaci (HAART). Epidemiol Prev 2003; 27:333-339.
30. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1727-1728.
31. Murri R, Fantoni M, Del Borgo C, Izzi I, Visona R, Suter F, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999; 22:461-466.